Dianthus Therapeutics (NASDAQ:DNTH) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of Dianthus Therapeutics (NASDAQ:DNTH) from an outperform rating to a strong-buy rating in a report published on Tuesday morning, MarketBeat Ratings reports. They currently have $123.00 target price on the stock, up from their prior target price of $63.00.

Other research analysts also recently issued reports about the company. Wedbush raised their price target on Dianthus Therapeutics from $55.00 to $80.00 and gave the company an “outperform” rating in a research note on Tuesday. Truist Financial increased their price objective on Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a report on Monday. Oppenheimer raised their target price on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday. HC Wainwright boosted their target price on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $115.33.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $80.32 on Tuesday. The company has a market cap of $3.57 billion, a price-to-earnings ratio of -19.59 and a beta of 1.56. The firm has a 50-day moving average of $51.76 and a 200-day moving average of $42.18. Dianthus Therapeutics has a one year low of $13.36 and a one year high of $88.02.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%. The company had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. As a group, sell-side analysts expect that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. Raymond James Financial Inc. bought a new position in Dianthus Therapeutics during the second quarter worth $27,000. Parkside Financial Bank & Trust increased its holdings in shares of Dianthus Therapeutics by 131.7% in the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock valued at $37,000 after purchasing an additional 540 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter valued at about $40,000. Russell Investments Group Ltd. acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth about $64,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Key Headlines Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Multiple analyst upgrades/positive notes pushed upside sentiment — Raymond James raised to Strong-Buy, Wedbush and Robert W. Baird published bullish commentary, and Truist raised its price target to $110. Raymond James Upgrade Wedbush Note Baird Note Truist PT Increase
• Neutral Sentiment: Dianthus closed its upsized underwritten offering: 8,470,989 common shares (plus pre-funded warrants), full exercise of the underwriters’ option, at $81.00 for gross proceeds of ~ $719M — strengthens the balance sheet and funds development but increases share count (dilution). Offering Close
• Neutral Sentiment: Prior pricing announcement (pricing of the upsized $625M offering before exercise) set the $81 deal terms and underwriter option that later pushed the deal to $719M; useful for timeline context. Offering Pricing
• Neutral Sentiment: Reported short interest entries show effectively zero reported short volume and a 0.0 days-to-cover figure (data may be placeholder/insignificant) — not a meaningful driver.
• Negative Sentiment: HC Wainwright sharply lowered near‑term and multi‑year EPS forecasts (Q1–Q4 2026 and FY2026–FY2028 trimmed substantially) while keeping a Buy and $130 target — the cuts signal updated modeling for higher costs or slower commercialization timelines and may weigh on near‑term sentiment. HC Wainwright Note (MarketBeat)

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.